Company Overview of Cardioxyl Pharmaceuticals, Inc.
Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of nitroxyl therapeutics for the treatment of cardiovascular diseases. It develops chemistry, biology, and clinical applications of nitroxyl technology; and provides CXL-1020, an initial nitroxyl donor clinical candidate for patients with acute decompensated heart failure. The company was founded in 2005 and is based in Chapel Hill, North Carolina. As of December 8, 2015, Cardioxyl Pharmaceuticals, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
1450 Raleigh Road
Chapel Hill, NC 27517
Founded in 2005
Key Executives for Cardioxyl Pharmaceuticals, Inc.
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Cardioxyl Pharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.